Factory 99% Upadacitinib Powder CAS 1310726-60-3 Chemical Intermediate Upadacitinib

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A837
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Upadacitinib
• CAS: 1310726-60-3
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Upadacitinib
Appearance	White Powder
CAS NO.	1310726-60-3
Storage	Keep in a cool, dry, dark location

 

Upadacitinib (ABT-494) is an oral, selective Janus kinase (JAK) inhibitor, specifically targeting JAK1. It belongs to a class of drugs known as "small molecule kinase inhibitors," which regulate immune responses by inhibiting specific intracellular signaling pathways.

 

1. Autoimmune Diseases: Upadacitinib has been approved for the treatment of various autoimmune diseases, including adult and pediatric (12 years and older) patients with atopic dermatitis (AD), rheumatoid arthritis (RA), and psoriatic arthritis (PsA).
2. Inflammatory Diseases: It demonstrates efficacy in clinical trials for the treatment of inflammatory conditions such as ulcerative colitis (UC).
3. Broad Coverage: In China, Upadacitinib is currently the JAK1 inhibitor with the most indications covered.

1. Immune Regulation: By selectively inhibiting JAK1, Upadacitinib reduces the production of inflammatory cytokines and inhibits the overactivation of the immune system. This helps to alleviate inflammation and symptoms associated with autoimmune diseases.
2. Symptom Relief: In patients with RA, UC, and AD, Upadacitinib has shown significant improvements in disease activity, joint function, skin lesions, and overall quality of life.
3. Safety and Efficacy: Upadacitinib is generally well-tolerated with a manageable side effect profile. However, patients should be monitored for potential adverse reactions such as infections, gastrointestinal issues, and changes in blood counts.